India

ICMR’s 3rd phase results show Covaxin effective against double mutation variant

The Indian Council of Medical Research (ICMR) gave good news on Tuesday. ICMR stated that its Corona vaccine – Covaxin also protects against double mutant corona variants. Based on its study, ICMR said that this vaccine is also effective on the Brazilian variant, the UK variant and the South African variant, and gives protection against them as well.

These variants are being blamed for the ongoing second wave in the country. The double mutant corona variant encountered in 10 states of India is the most fatal. It not only transmits rapidly, but also causes a lot of damage in a very short period of time. At the same time, UK, Brazil and South African variants have also emerged in the growing re-infection cases in India.

Covaxin effective up to 78% in third phase clinical trials

Bharat Biotech, a Hyderabad-based company that manufactures the Corona vaccine, and the Indian Council of Medical Research (ICMR) have released an interim clinical trial report for the third phase of Covaxin. The report described Covaxin manufactured in India as clinically 78% and up to 100% effective on patients severely affected by Corona. The company, in its second analysis, did research on Corona’s 87 symptoms.

The company subsequently analyzed 127 symptoms for the third phase following the increased infection. In this, Covaxin efficacy was found to be up to 78%. The company will release the final vaccine report in June. The third phase study included 25,800 people between the ages of 18–98, with 10% of those over 60 years.

What does it mean?

Bharat Biotech has made Covaxin on a traditional platform. In this, inactivated virus is injected into the body, which does not grow in the body, but it prepares antibodies to fight it. The good thing is that it targets the entire virus, so it is effective even on the changes that occur in it. As per the data suggested, Covaxin is the first such vaccine in the world, which has the power to fight all the variants.

Trouble in triple mutant variant in Maharashtra- Delhi

ICMR has given relief news about Covaxin, as the country battles the second wave of Coronavirus. According to scientists, the triple mutant variant of Corona is now spreading in the country. This new variant is made up of three different strains of Corona. Experts believe that in states like Delhi, Bengal and Maharashtra, people are falling prey to this variant.

Trial results were much better

The trial of indigenous Covaxin has yielded much better results. According to the final results of the Phase-3 clinical trials, the vaccine has proved to be effective up to 81%. The government had given emergency approval to the vaccine in the first week of January. This decision of the government was on the target of experts as they were against Emergency Approval without seeing the Phase-3 results.

Covaxin effective against all variants of Corona

Dr. Krishna Ella, chairman and managing director of Bharat Biotech, says that the vaccine has been used on 27,000 volunteers in all three phases of clinical trials. With the results of Phase-3 clinical trials, it has been proven that Covaxin is effective against coronaviruses. This vaccine is also effective against other variants of coronavirus that are rapidly emerging.

Show More

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button